Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. (PBM) covers the month of February 2026. The report details the ratification and execution of a Share Put Option and Amendment Agreement with Psyence Labs Ltd. (PsyLabs), a related party. The transaction involves a share-for-share exchange rather than a cash transaction.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. Instead, it outlines the following specific transaction metrics:
- Subscription Amount: US$5,000,000.
- PsyLabs Shares Issued to PBM: 2,900 shares (valued at US$5,000,000 based on a PsyLabs fair market valuation of US$1,724,000,000).
- PBM Shares Issued to PsyLabs: 1,146,159 common shares.
- Share Pricing Basis: Calculated using a 30-day VWAP of US$4.36 per share for PBM.
- Cash Consideration: None.
- Post-Transaction Ownership: PsyLabs will beneficially own approximately 49.98% of PBM's issued and outstanding common shares.
Material Changes Versus Prior Period
The primary material change is the significant increase in PsyLabs' ownership stake in PBM, rising to approximately 49.98% following the issuance of new PBM shares. This transaction was ratified by the Board on February 10, 2026, and an Exercise Notice was received on February 13, 2026. The filing notes that prior to this issuance, there were 1,147,148 common shares outstanding.
Guidance, Outlook, Risks, and Contingencies
Outlook and Timing: The Company expects to consummate the Share Exchange on or about February 25, 2026, subject to the satisfaction of conditions precedent.
Risks and Related-Party Considerations: The transaction is classified as a related-party transaction under Canadian corporate law and Nasdaq rules because certain PBM management members are affiliates of PsyLabs and hold financial interests there. To mitigate conflicts of interest, a Special Committee of independent directors reviewed the deal, evaluated an independent third-party valuation, and recommended approval. Conflicted directors recused themselves from voting.
Regulatory Contingencies: The issuance of PBM shares relies on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Regulation S. The shares will be issued as restricted securities.
Important Facts for Investor Verification
- Verify the final closing date of the Share Exchange, currently expected around February 25, 2026.
- Confirm the exact post-closing share count and the resulting 49.98% ownership stake held by PsyLabs.
- Review the full text of the Share Put Option and Amendment Agreement (Exhibit 10.1) for specific conditions precedent and bring-down conditions.
- Assess the impact of PsyLabs becoming a near-majority shareholder on future corporate governance and strategic direction.
- Monitor for any subsequent filings regarding the registration status of the restricted PBM shares issued to PsyLabs.